ArticleArthritis & rheumatology (Hoboken, N.J.)2016
A Novel Mechanism for Generating the Interferon Signature in Lupus: Opsonization of Dead Cells by Complement and IgM.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- A symposium update on the key perspectives in systemic sclerosis and systemic lupus erythematosus.Journal of translational autoimmunity · 2026Review
- Hair follicle immune privilege in autoimmune and immune-mediated alopecias: paths toward reestablishing immune tolerance.Frontiers in medicine · 2026Review
- Decoding the genetic landscape of juvenile dermatomyositis: insights from phosphorylation-associated single nucleotide polymorphisms.Immunogenetics · 2024Article
- The complement system and human autoimmune diseases.Journal of autoimmunity · 2023Review
- Pericardial and mediastinal fat-associated lymphoid clusters are rapidly activated in an alkane-induced model of systemic lupus erythematosus.Discovery immunology · 2023Article
- NOX2 mediates quiescent handling of dead cell remnants in phagocytes.Redox biology · 2019Article
- The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2017Review
- Pristane-induced lupus: considerations on this experimental model.Clinical rheumatology · 2017Review
- A Novel Subset of Anti-Inflammatory CD138Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Pathogenesis of Diffuse Alveolar Hemorrhage in Murine Lupus.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- The Microbiome in Connective Tissue Diseases and Vasculitides: An Updated Narrative Review.Journal of immunology research · 2017Review
- Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis.F1000Research · 2017Review
- "Lupoid hepatitis" in SLE patients and mice with experimental lupus.Clinical immunology (Orlando, Fla.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveIn vitro studies suggest that the type I interferon (IFN) signature seen in most lupus patients results from Fcγ receptor-mediated uptake of nucleic acid-containing immune complexes by plasmacytoid dendritic cells and engagement of endosomal Toll-like receptors. The aim of this study was to reexamine the pathogenesis of the IFN signature in vivo.
methodsLupus was induced in mice by injecting pristane. Some mice were treated with normal immunoglobulin or with cobra venom factor to deplete complement. The IFN signature was evaluated by polymerase chain reaction. The IFN signature also was determined in C4-deficient patients and control subjects.
resultsWild-type C57BL/6 mice with pristane-induced lupus developed a strong IFN signature, which was absent in immunoglobulin-deficient (μMT), C3
conclusionThese studies define previously unrecognized roles of natural IgM, complement, and complement receptors in generating the IFN signature in lupus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.